P-154 A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015

Abstract

Combination chemotherapy with fluoropyrimidine and platinum is recommended by the National Comprehensive Cancer Network as a first-line treatment option for patients with locally advanced recurrent and/or metastatic gastric cancer; however, there is a need for more effective therapies. PD-1 inhibitor pembrolizumab in combination with the RTK inhibitor lenvatinib previously demonstrated antitumor activity and acceptable safety in advanced gastroesophageal adenocarcinoma. Pembrolizumab plus lenvatinib plus platinum-doublet chemotherapy also showed acceptable safety in metastatic non–small cell lung cancer in the phase 3 LEAP-006 study.